RE:RE:RE:ENDPYes, thank you Lattice. After reading your posts at the end of April and the Marc Cohodes interview I did more due diligence and then I exited my position shortly after. Saved me a bundle. And unfortunately a week ago I discovered that they have to be 1 of 4 companies under investigation in the UK based on these 2 stories below. So again, unfortunately, I agree with Lattice that there's more to come.
https://healthunlocked.com/thyroiduk/posts/133679011/t3-billy-has-uncovered-yet-another-surprise. https://www.telegraph.co.uk/news/2016/06/04/watchdog-to-investigate-extortionate-drugs-pricing-claims/ Craigbad wrote: Be careful in your assumption that all bad news is out. If Donnatal gets pulled or they are one of the companies under investigation in the Uk this could easily fall into single digit support of $7-8. Hard to see funds buying this with clients money but easy to see funds start to dump. A shoutout goes to Lattice for calling this and taking all the abuse from blinded longs. You saved innocent retail investors who kept an objective view alot of money.
subwave wrote: Get real...the last chance for the shorts to cover. EPS 1,38 /Q2 is 5,52 per year, a steal around 20 bucks. All bad news out now.
- Second quarter 2016 revenue of $231.7 million, an increase of 1.4 per cent over the first quarter of 2016 and 208 per cent over the second quarter of 2015
- Reported second quarter GAAP net loss of $570.5 million, GAAP earnings per share loss of $11.18, which was primarily due to an adjustment to the carrying values of Nilandron® and Plaquenil® by $567 million due to generic competition
- Second quarter 2016 adjusted EBITDA1 of $142.3 million and adjusted earnings per share of $1.38
- Concordia's International segment launched 13 new products since October 21, 2015; the Company remains on track to meet its target of 60 plus launches in the next three years
- Revises 2016 guidance2 to US$859 million to US$888 million of revenue and adjusted EBITDA1 to US$510 million to US$540 million